ERBB2 and gastric cancer: Overall, 161 patients with stage I–III, centrally determined HER2 overexpressing GC and GEJ tumors were randomly allocated 1:1:2 into three perioperative treatment arms: chemotherapy alone (arm A), chemotherapy plus trastuzumab (arm B), or chemotherapy in combination with trastuzumab and pertuzumab (arm C).